-
2
-
-
0035077234
-
Definitions in hemophilia: Recommendations of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis
-
White II GC, Rosendaal F, Aledort LM, et al. Definitions in hemophilia: recommendations of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis [letter]. Thromb Haemost 2001; 85: 560
-
(2001)
Thromb Haemost
, vol.85
, pp. 560
-
-
White II, G.C.1
Rosendaal, F.2
Aledort, L.M.3
-
3
-
-
0042411064
-
Consensus perspectives on prophylactic therapy for haemophilia: Summary statement
-
Berntorp E, Astermark J, Bjorkman S, et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003; 9 Suppl. 1: 1-4
-
(2003)
Haemophilia
, vol.9
, Issue.1 SUPPL.
, pp. 1-4
-
-
Berntorp, E.1
Astermark, J.2
Bjorkman, S.3
-
4
-
-
0036207230
-
Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients
-
Royal S, Schramm W, Berntorp E, et al. Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia 2002; 8: 44-50
-
(2002)
Haemophilia
, vol.8
, pp. 44-50
-
-
Royal, S.1
Schramm, W.2
Berntorp, E.3
-
5
-
-
0029931340
-
Inhibitors in congenital haemophilia
-
Brettler DB. Inhibitors in congenital haemophilia. Baillieres Clin Haematol 1996; 9: 319-29
-
(1996)
Baillieres Clin Haematol
, vol.9
, pp. 319-329
-
-
Brettler, D.B.1
-
6
-
-
0038383605
-
The epidemiology of inhibitors in haemophilia A: A systematic review
-
Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35
-
(2003)
Haemophilia
, vol.9
, pp. 418-435
-
-
Wight, J.1
Paisley, S.2
-
7
-
-
0033768130
-
The diagnosis and management of factor VIII and factor IX inhibitors: A guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO)
-
Hay CRM, Baglin TP, Collins PW, et al. The diagnosis and management of factor VIII and factor IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO). Br J Haematol 2000; 111: 78-90
-
(2000)
Br J Haematol
, vol.111
, pp. 78-90
-
-
Hay, C.R.M.1
Baglin, T.P.2
Collins, P.W.3
-
8
-
-
0027520025
-
Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A
-
Lakich D, Kazazian HH, Antonarakis SE, et al. Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nat Genet 1993; 5: 236-41
-
(1993)
Nat Genet
, vol.5
, pp. 236-241
-
-
Lakich, D.1
Kazazian, H.H.2
Antonarakis, S.E.3
-
9
-
-
0025017341
-
The increasing prevalence of haemophilia
-
Rosendaal FR, Briët E. The increasing prevalence of haemophilia [letter]. Thromb Haemost 1990; 63: 145
-
(1990)
Thromb Haemost
, vol.63
, pp. 145
-
-
Rosendaal, F.R.1
Briët, E.2
-
10
-
-
0013856638
-
Production of high potency concentrates of antihemophilic globulin in a closed bag system: Assay in vitro and in vivo
-
Pool JG, Shannon AE. Production of high potency concentrates of antihemophilic globulin in a closed bag system: assay in vitro and in vivo. N Engl J Med 1965; 273: 1443-7
-
(1965)
N Engl J Med
, vol.273
, pp. 1443-1447
-
-
Pool, J.G.1
Shannon, A.E.2
-
11
-
-
0022002357
-
Life expectancy of Swedish haemophiliacs, 1831-1980
-
Larsson SA. Life expectancy of Swedish haemophiliacs, 1831-1980. Br J Haematol 1985; 59: 593-602
-
(1985)
Br J Haematol
, vol.59
, pp. 593-602
-
-
Larsson, S.A.1
-
12
-
-
0020662433
-
Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-1980: Report on behalf of the directors of haemophilia centres in the United Kingdom
-
Rizza CR, Spooner RJD. Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-1980: report on behalf of the directors of haemophilia centres in the United Kingdom. BMJ 1983; 286: 929-33
-
(1983)
BMJ
, vol.286
, pp. 929-933
-
-
Rizza, C.R.1
Spooner, R.J.D.2
-
13
-
-
0029157066
-
Mortality before and after HIV infection in the complete UK population of haemophiliacs
-
Darby SC, Ewart DW, Giangrande PLF, et al. Mortality before and after HIV infection in the complete UK population of haemophiliacs. Nature 1995; 377: 79-82
-
(1995)
Nature
, vol.377
, pp. 79-82
-
-
Darby, S.C.1
Ewart, D.W.2
Giangrande, P.L.F.3
-
14
-
-
0031583763
-
Mortality from liver cancer and liver disease in haemophilic men and boys given blood products contaminated with hepatitis C
-
Darby SC, Ewart DW, Giangrande PLF, et al. Mortality from liver cancer and liver disease in haemophilic men and boys given blood products contaminated with hepatitis C. Lancet 1997; 350: 1425-31
-
(1997)
Lancet
, vol.350
, pp. 1425-1431
-
-
Darby, S.C.1
Ewart, D.W.2
Giangrande, P.L.F.3
-
15
-
-
0024492443
-
Physical condition, longevity and social performance of Dutch haemophiliacs, 1972-1985
-
Smit C, Rosendaal FR, Varekamp I, et al. Physical condition, longevity and social performance of Dutch haemophiliacs, 1972-1985. BMJ 1989; 298: 235-8
-
(1989)
BMJ
, vol.298
, pp. 235-238
-
-
Smit, C.1
Rosendaal, F.R.2
Varekamp, I.3
-
17
-
-
0034661520
-
Mortality among males with hemophilia: Relations with source of medical care
-
Soucie JM, Nuss R, Evatt B, et al. Mortality among males with hemophilia: relations with source of medical care. Blood 2000; 96: 437-42
-
(2000)
Blood
, vol.96
, pp. 437-442
-
-
Soucie, J.M.1
Nuss, R.2
Evatt, B.3
-
18
-
-
0037388669
-
Factor concentrate usage in persons with hemophilia in New York State
-
Linden JV, Kolakoski MH, Lima JE, et al. Factor concentrate usage in persons with hemophilia in New York State. Transfusion 2003; 43: 470-5
-
(2003)
Transfusion
, vol.43
, pp. 470-475
-
-
Linden, J.V.1
Kolakoski, M.H.2
Lima, J.E.3
-
20
-
-
0025997234
-
The impact of a very high purity factor VIII concentrate on the immune system of human immunodeficiency virus-infected hemophiliacs: A randomized, prospective, two-year comparison with an intermediate purity concentrate
-
De Biasi R, Rocino A, Miraglia E, et al. The impact of a very high purity factor VIII concentrate on the immune system of human immunodeficiency virus-infected hemophiliacs: a randomized, prospective, two-year comparison with an intermediate purity concentrate. Blood 1991; 78: 1919-22
-
(1991)
Blood
, vol.78
, pp. 1919-1922
-
-
De Biasi, R.1
Rocino, A.2
Miraglia, E.3
-
21
-
-
0028093461
-
Risks of immunodeficiency, AIDS and death related to purity of factor VIII concentrate: Multicenter Hemophilia Cohort Study
-
Goedert JJ, Cohen AR, Kessler CM. Risks of immunodeficiency, AIDS and death related to purity of factor VIII concentrate: Multicenter Hemophilia Cohort Study. Lancet 1994; 344: 791-2
-
(1994)
Lancet
, vol.344
, pp. 791-792
-
-
Goedert, J.J.1
Cohen, A.R.2
Kessler, C.M.3
-
22
-
-
0028047984
-
CD4+ counts before and after switching to monoclonally high-purity factor VIII concentrate in HIV-infected haemophilic patients
-
Sabin C, Pasi J, Phillips A, et al. CD4+ counts before and after switching to monoclonally high-purity factor VIII concentrate in HIV-infected haemophilic patients. Thromb Haemost 1994; 72: 214-7
-
(1994)
Thromb Haemost
, vol.72
, pp. 214-217
-
-
Sabin, C.1
Pasi, J.2
Phillips, A.3
-
23
-
-
0031803244
-
The effect of monoclonal or ion-exchange purified factor VIII concentrate on HIV disease progression: A prospective cohort comparison
-
Hay CR, Ludlam CA, Lowe GD, et al. The effect of monoclonal or ion-exchange purified factor VIII concentrate on HIV disease progression: a prospective cohort comparison. Br J Haematol 1998; 101: 632-7
-
(1998)
Br J Haematol
, vol.101
, pp. 632-637
-
-
Hay, C.R.1
Ludlam, C.A.2
Lowe, G.D.3
-
24
-
-
0027980561
-
A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate
-
Thomas DP, Hampton KK, Dasani H, et al. A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate. Br J Haematol 1994; 87: 782-8
-
(1994)
Br J Haematol
, vol.87
, pp. 782-788
-
-
Thomas, D.P.1
Hampton, K.K.2
Dasani, H.3
-
25
-
-
0016833191
-
Thromboembolic complications
-
Kasper CK. Thromboembolic complications. Thromb Diath Haemorrh 1975; 33: 640-4
-
(1975)
Thromb Diath Haemorrh
, vol.33
, pp. 640-644
-
-
Kasper, C.K.1
-
26
-
-
0025168938
-
Disseminated intravascular coagulation and hemorrhage in hemophilia B following elective surgery
-
Conlan MG, Hoots WK. Disseminated intravascular coagulation and hemorrhage in hemophilia B following elective surgery. Am J Hematol 1990; 35: 203-7
-
(1990)
Am J Hematol
, vol.35
, pp. 203-207
-
-
Conlan, M.G.1
Hoots, W.K.2
-
27
-
-
0019455712
-
Myocardial infarction after factor IX therapy
-
Fuerth JH, Mahrer P. Myocardial infarction after factor IX therapy. JAMA 1981; 245: 1455-6
-
(1981)
JAMA
, vol.245
, pp. 1455-1456
-
-
Fuerth, J.H.1
Mahrer, P.2
-
28
-
-
0023752997
-
Virus safety of solvent/detergent-treated antihaemophilic factor concentrate
-
Horowitz MS, Rooks C, Horowitz B, et al. Virus safety of solvent/detergent-treated antihaemophilic factor concentrate. Lancet 1988; II: 186-9
-
(1988)
Lancet
, vol.2
, pp. 186-189
-
-
Horowitz, M.S.1
Rooks, C.2
Horowitz, B.3
-
29
-
-
0024357699
-
Absence of anti-human immunodeficiency virus types 1 and 2 seroconversion after the treatment of hemophilia A or von Willebrand's disease with pasteurized factor VIII concentrate
-
Schimpf K, Brackmann HH, Kreuz W, et al. Absence of anti-human immunodeficiency virus types 1 and 2 seroconversion after the treatment of hemophilia A or von Willebrand's disease with pasteurized factor VIII concentrate. N Engl J Med 1989; 321: 1148-52
-
(1989)
N Engl J Med
, vol.321
, pp. 1148-1152
-
-
Schimpf, K.1
Brackmann, H.H.2
Kreuz, W.3
-
30
-
-
0027213353
-
Confirmation of viral safety of dry heated factor VIII concentrate (8Y) prepared by Bio Products Laboratory (BPL): A report on behalf of UK Haemophilia Centre Directors
-
Rizza CR, Fletcher ML, Kernoff PB. Confirmation of viral safety of dry heated factor VIII concentrate (8Y) prepared by Bio Products Laboratory (BPL): a report on behalf of UK Haemophilia Centre Directors. Br J Haematol 1993; 84: 269-72
-
(1993)
Br J Haematol
, vol.84
, pp. 269-272
-
-
Rizza, C.R.1
Fletcher, M.L.2
Kernoff, P.B.3
-
31
-
-
0028136537
-
Review of the hepatitis A epidemics in hemophiliacs in Europe
-
Vermylen J, Peerlinck K. Review of the hepatitis A epidemics in hemophiliacs in Europe. Vox Sang 1994; 67 Suppl. 4: 8-11
-
(1994)
Vox Sang
, vol.67
, Issue.4 SUPPL.
, pp. 8-11
-
-
Vermylen, J.1
Peerlinck, K.2
-
32
-
-
0031846936
-
Hepatitis A virus infections associated with clotting factor concentrate in the United States
-
Soucie JM, Roberston BH, Bell BP, et al. Hepatitis A virus infections associated with clotting factor concentrate in the United States. Transfusion 1998; 38: 573-9
-
(1998)
Transfusion
, vol.38
, pp. 573-579
-
-
Soucie, J.M.1
Roberston, B.H.2
Bell, B.P.3
-
33
-
-
0029983755
-
Transmission of symptomatic parvovirus parvovirus B19 infection by clotting factor concentrate
-
Yee TT, Cohen BJ, Pasi KJ, et al. Transmission of symptomatic parvovirus parvovirus B19 infection by clotting factor concentrate. Br J Haematol 1996; 93: 457-9
-
(1996)
Br J Haematol
, vol.93
, pp. 457-459
-
-
Yee, T.T.1
Cohen, B.J.2
Pasi, K.J.3
-
34
-
-
0033067602
-
The transfusion-associated transmission of parvovirus B19
-
Azzi A, Morfini M, Mannucci PM. The transfusion-associated transmission of parvovirus B19. Transfus Med Rev 1999; 13: 194-204
-
(1999)
Transfus Med Rev
, vol.13
, pp. 194-204
-
-
Azzi, A.1
Morfini, M.2
Mannucci, P.M.3
-
35
-
-
0036588695
-
Risk of variant Creutzfeldt-Jakob disease from factor concentrates: Current perspectives
-
Farrugia A. Risk of variant Creutzfeldt-Jakob disease from factor concentrates: current perspectives. Haemophilia 2002; 8: 230-5
-
(2002)
Haemophilia
, vol.8
, pp. 230-235
-
-
Farrugia, A.1
-
36
-
-
0037276210
-
Nanofiltration of plasma-derived biopharmaceutical products
-
Burnouf T, Radosevich M. Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia 2003; 9: 24-37
-
(2003)
Haemophilia
, vol.9
, pp. 24-37
-
-
Burnouf, T.1
Radosevich, M.2
-
37
-
-
0037279116
-
Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders
-
United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO). Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 2003; 9: 1-23
-
(2003)
Haemophilia
, vol.9
, pp. 1-23
-
-
-
38
-
-
0141955859
-
Immunization of patients with bleeding disorders
-
Makris M, Conlon CP, Watson HG. Immunization of patients with bleeding disorders. Haemophilia 2003; 9: 541-6
-
(2003)
Haemophilia
, vol.9
, pp. 541-546
-
-
Makris, M.1
Conlon, C.P.2
Watson, H.G.3
-
39
-
-
0028884285
-
PCR detection of a low viral load in a prothrombin complex concentrate that transmitted hepatitis B virus
-
Jantsch-Plunger V, Beck G, Maurer W. PCR detection of a low viral load in a prothrombin complex concentrate that transmitted hepatitis B virus. Vox Sang 1995; 69: 352-4
-
(1995)
Vox Sang
, vol.69
, pp. 352-354
-
-
Jantsch-Plunger, V.1
Beck, G.2
Maurer, W.3
-
40
-
-
0141673367
-
Treatment of hemophilia: Recombinant products only? Yes
-
Giangrande PLF. Treatment of hemophilia: recombinant products only? Yes. J Thromb Haemost 2003; 1: 214-5
-
(2003)
J Thromb Haemost
, vol.1
, pp. 214-215
-
-
Giangrande, P.L.F.1
-
41
-
-
0141785315
-
Treatment of hemophilia; recombinant products only? No
-
Mannucci PM. Treatment of hemophilia; recombinant products only? No. J Thromb Haemost 2003; 1: 216-7
-
(2003)
J Thromb Haemost
, vol.1
, pp. 216-217
-
-
Mannucci, P.M.1
-
42
-
-
0344450955
-
Parvovirus B19 DNA is frequently present in recombinant coagulation factor VIII products
-
Eis-Hübinger AM, Sasowski U, Brackmann HH, et al. Parvovirus B19 DNA is frequently present in recombinant coagulation factor VIII products [letter]. Thromb Haemost 1996; 76: 1120
-
(1996)
Thromb Haemost
, vol.76
, pp. 1120
-
-
Eis-Hübinger, A.M.1
Sasowski, U.2
Brackmann, H.H.3
-
43
-
-
0035889161
-
TT virus contaminates first-generation recombinant factor VIII concentrates
-
Azzi A, De Santis R, Morfini M, et al. TT virus contaminates first-generation recombinant factor VIII concentrates. Blood 2001; 15: 2571-3
-
(2001)
Blood
, vol.15
, pp. 2571-2573
-
-
Azzi, A.1
De Santis, R.2
Morfini, M.3
-
44
-
-
0027416074
-
Hepatitis C viral RNA in clotting factor concentrates and the development of hepatitis in recipients
-
Makris M, Garson JA, Ring CJ, et al. Hepatitis C viral RNA in clotting factor concentrates and the development of hepatitis in recipients. Blood 1993; 81: 1898-902
-
(1993)
Blood
, vol.81
, pp. 1898-1902
-
-
Makris, M.1
Garson, J.A.2
Ring, C.J.3
-
45
-
-
0036843096
-
Transmission of prion diseases by blood transfusion
-
Hunter N, Foster J, Chong A, et al. Transmission of prion diseases by blood transfusion. J Gen Virol 2002; 83: 2897-905
-
(2002)
J Gen Virol
, vol.83
, pp. 2897-2905
-
-
Hunter, N.1
Foster, J.2
Chong, A.3
-
47
-
-
3843101074
-
-
online
-
Phillips Report on the BSE Inquiry in the UK (2000) [online]. Available from URL: www.bseinquiry.gov.uk/report/volume10/chaptef2.htm#260106 [Accessed 2004 May 27]
-
(2000)
Phillips Report on the BSE Inquiry in the UK
-
-
-
48
-
-
0033678089
-
Factor VIII inhibitors with recombinant products: Prospective clinical trials
-
Lusher JM. Factor VIII inhibitors with recombinant products: prospective clinical trials. Haematologica 2000; 85 Suppl. 10: 2-6
-
(2000)
Haematologica
, vol.85
, Issue.10 SUPPL.
, pp. 2-6
-
-
Lusher, J.M.1
-
49
-
-
0034917204
-
Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A
-
Mauser-Bunschoten EP, van der Born JG, Bongers M, et al. Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A. Haemophilia 2001; 7: 364-8
-
(2001)
Haemophilia
, vol.7
, pp. 364-368
-
-
Mauser-Bunschoten, E.P.1
Van Der Born, J.G.2
Bongers, M.3
-
50
-
-
0032787813
-
Incidence of inhibitors in haemophilia A patients: A review of recent studies of recombinant and plasma-derived factor VIII concentrates
-
Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients: a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999; 5: 145-54
-
(1999)
Haemophilia
, vol.5
, pp. 145-154
-
-
Scharrer, I.1
Bray, G.L.2
Neutzling, O.3
-
51
-
-
0036332175
-
Von Willebrand factor modulates factor VIIII immunogenicity: Comparative study of different factor VIII concentrates in a haemophilia A mouse model
-
Behrmann M, Pasi J, Saint-Remy J-M. et al. Von Willebrand factor modulates factor VIIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemost 2002; 88: 221-229
-
(2002)
Thromb Haemost
, vol.88
, pp. 221-229
-
-
Behrmann, M.1
Pasi, J.2
Saint-Remy, J.-M.3
-
52
-
-
2542560221
-
The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients
-
Auerswald G, Spranger T, Brackmann H-H. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica 2003; 88 Suppl. 9: 21-5
-
(2003)
Haematologica
, vol.88
, Issue.9 SUPPL.
, pp. 21-25
-
-
Auerswald, G.1
Spranger, T.2
Brackmann, H.-H.3
-
53
-
-
0347662157
-
Surveillance for factor VIII inhibitor development in the Canadian hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy
-
Giles AR, Rivard GE, Teitel J, et al. Surveillance for factor VIII inhibitor development in the Canadian hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci 1998; 19: 139-48
-
(1998)
Transfus Sci
, vol.19
, pp. 139-148
-
-
Giles, A.R.1
Rivard, G.E.2
Teitel, J.3
-
54
-
-
0036123458
-
Recombinant factor IX recovery and inhibitor safety: A Canadian post-licensure surveillance study
-
Poon M-C, Lillicrap D, Hensman C, et al. Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study. Thromb Haemost 2002; 87: 431-5
-
(2002)
Thromb Haemost
, vol.87
, pp. 431-435
-
-
Poon, M.-C.1
Lillicrap, D.2
Hensman, C.3
-
55
-
-
0036249147
-
Inhibitor development in correlation to factor VIII genotypes
-
Oldenburg J, El-Maari O, Schwaab R. Inhibitor development in correlation to factor VIII genotypes. Haemophilia 2002; 8 Suppl. 2: 23-9
-
(2002)
Haemophilia
, vol.8
, Issue.2 SUPPL.
, pp. 23-29
-
-
Oldenburg, J.1
El-Maari, O.2
Schwaab, R.3
-
56
-
-
0037810809
-
Standardization of FVIII and FIX assays
-
Barrowcliffe TW. Standardization of FVIII and FIX assays. Haemophilia 2003; 9: 397-402
-
(2003)
Haemophilia
, vol.9
, pp. 397-402
-
-
Barrowcliffe, T.W.1
-
57
-
-
0036223409
-
A survey of one-stage and chromogenic potencies in therapeutic factor VIII concentrates
-
Hubbard AR, Weller LJ, Bevan SA. A survey of one-stage and chromogenic potencies in therapeutic factor VIII concentrates. Br J Haematol 2002; 117: 247-8
-
(2002)
Br J Haematol
, vol.117
, pp. 247-248
-
-
Hubbard, A.R.1
Weller, L.J.2
Bevan, S.A.3
-
58
-
-
0032751069
-
Pharmacokinetics of recombinant factor VIII (Recombinate) using one-stage clotting and chromogenic factor VIII assay
-
Lee CA, Owens D, Bray G, et al. Pharmacokinetics of recombinant factor VIII (Recombinate) using one-stage clotting and chromogenic factor VIII assay. Thromb Haemost 1999; 82: 1644-7
-
(1999)
Thromb Haemost
, vol.82
, pp. 1644-1647
-
-
Lee, C.A.1
Owens, D.2
Bray, G.3
-
59
-
-
0031828437
-
Discrepancies in potency assessment of recombinant FVIII concentrates
-
Barrowcliffe TW, Raut S, Hubbard AR. Discrepancies in potency assessment of recombinant FVIII concentrates. Haemophilia 1998; 4: 634-40
-
(1998)
Haemophilia
, vol.4
, pp. 634-640
-
-
Barrowcliffe, T.W.1
Raut, S.2
Hubbard, A.R.3
-
60
-
-
0031878077
-
Influence of phospholipids on the assessment of factor VIII activity
-
Mikaelsson M, Oswaldsson U, Sandberg H. Influence of phospholipids on the assessment of factor VIII activity. Haemophilia 1998; 4: 646-50
-
(1998)
Haemophilia
, vol.4
, pp. 646-650
-
-
Mikaelsson, M.1
Oswaldsson, U.2
Sandberg, H.3
-
61
-
-
0034952586
-
Measurement of factor VIII activity of B-domain deleted recombinant factor VIII
-
Mikaelsson M, Oswaldsson U, Jankowski MA. Measurement of factor VIII activity of B-domain deleted recombinant factor VIII. Semin Hematol 2001; 38 Suppl. 4: 13-23
-
(2001)
Semin Hematol
, vol.38
, Issue.4 SUPPL.
, pp. 13-23
-
-
Mikaelsson, M.1
Oswaldsson, U.2
Jankowski, M.A.3
-
62
-
-
0347588517
-
Health-related quality of life assessment in adult haemophilia patients: A systematic review and evaluation of instruments
-
Szende A, Schramm W, Flood E, et al. Health-related quality of life assessment in adult haemophilia patients: a systematic review and evaluation of instruments. Haemophilia 2003; 9: 678-87
-
(2003)
Haemophilia
, vol.9
, pp. 678-687
-
-
Szende, A.1
Schramm, W.2
Flood, E.3
-
63
-
-
18344390038
-
Pilot testing of the 'Haemo-QoL' quality of life questionnaire for haemophiliac children in six European countries
-
Bullinger M, Von Mackensen S, Fischer K, et al. Pilot testing of the 'Haemo-QoL' quality of life questionnaire for haemophiliac children in six European countries. Haemophilia. 2002; 8 Suppl. 2: 47-54
-
(2002)
Haemophilia
, vol.8
, Issue.2 SUPPL.
, pp. 47-54
-
-
Bullinger, M.1
Von Mackensen, S.2
Fischer, K.3
-
64
-
-
0141482007
-
Cost of care and quality of life in hemophilia complicated by inhibitors: The COCIS Study Group
-
Gringeri A, Mantovani LG, Scalone L, et al. Cost of care and quality of life in hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-63
-
(2003)
Blood
, vol.102
, pp. 2358-2363
-
-
Gringeri, A.1
Mantovani, L.G.2
Scalone, L.3
-
65
-
-
2542576831
-
Global haemophilia care: Future challenges and opportunities
-
O' Mahony B. Global haemophilia care: future challenges and opportunities [abstract]. Haemophilia 2002; 8: 515
-
(2002)
Haemophilia
, vol.8
, pp. 515
-
-
O' Mahony, B.1
-
67
-
-
0035102942
-
A novel, automated method of temperature cycling to produce cryoprecipitate
-
Rock G, Berger R, Lange J, et al. A novel, automated method of temperature cycling to produce cryoprecipitate. Transfusion 2001; 41: 232-5
-
(2001)
Transfusion
, vol.41
, pp. 232-235
-
-
Rock, G.1
Berger, R.2
Lange, J.3
-
68
-
-
0032750252
-
Haemophilia therapy: Assessing the cumulative risk of HIV exposure by cryoprecipitate
-
Evatt BL, Austin H, Leon G, et al. Haemophilia therapy: assessing the cumulative risk of HIV exposure by cryoprecipitate. Haemophilia 1999; 5: 295-300
-
(1999)
Haemophilia
, vol.5
, pp. 295-300
-
-
Evatt, B.L.1
Austin, H.2
Leon, G.3
-
69
-
-
0038170070
-
Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A
-
Saenko EL, Ananyeva NM, Moayeri M, et al. Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A. Curr Gene Ther 2003; 3: 27-41
-
(2003)
Curr Gene Ther
, vol.3
, pp. 27-41
-
-
Saenko, E.L.1
Ananyeva, N.M.2
Moayeri, M.3
-
70
-
-
2542543315
-
The future of recombinant coagulation factor proteins
-
Saenko EL, Ananayeva NM, Shima M, et al. The future of recombinant coagulation factor proteins. J Thromb Haemost 2003; 1: 922-30
-
(2003)
J Thromb Haemost
, vol.1
, pp. 922-930
-
-
Saenko, E.L.1
Ananayeva, N.M.2
Shima, M.3
-
71
-
-
0030664471
-
Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa
-
Pipe SW, Kaufman RJ. Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proc Natl Acad Sci U S A 1997; 94 (22): 11851-6
-
(1997)
Proc Natl Acad Sci U S A
, vol.94
, Issue.22
, pp. 11851-11856
-
-
Pipe, S.W.1
Kaufman, R.J.2
-
72
-
-
0035853843
-
Cell surface heparin sulphate proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein receptor-related protein
-
Sarafanov AG, Ananyeva NM, Shima M, et al. Cell surface heparin sulphate proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein receptor-related protein. J Biol Chem 2001; 276: 11970-9
-
(2001)
J Biol Chem
, vol.276
, pp. 11970-11979
-
-
Sarafanov, A.G.1
Ananyeva, N.M.2
Shima, M.3
-
73
-
-
0034651022
-
Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules
-
Barrow RT, Healey JF, Gailani D, et al. Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. Blood 2000; 95: 564-8
-
(2000)
Blood
, vol.95
, pp. 564-568
-
-
Barrow, R.T.1
Healey, J.F.2
Gailani, D.3
-
74
-
-
1942521325
-
Bioengineering of coagulation factor VIII for improved secretion
-
May 1
-
Miao HZ, Sirachainan N, Palmer L, et al. Bioengineering of coagulation factor VIII for improved secretion. Blood 2004 May 1; 103 (9): 3412-9
-
(2004)
Blood
, vol.103
, Issue.9
, pp. 3412-3419
-
-
Miao, H.Z.1
Sirachainan, N.2
Palmer, L.3
-
75
-
-
0030771837
-
Transgenic pigs produce functional human factor VIII in milk
-
Paleyanda RK, Velander WH, Lee TK, et al. Transgenic pigs produce functional human factor VIII in milk. Nat Biotechnol 1997; 15: 971-5
-
(1997)
Nat Biotechnol
, vol.15
, pp. 971-975
-
-
Paleyanda, R.K.1
Velander, W.H.2
Lee, T.K.3
-
76
-
-
0033512496
-
Transgenic milk as a method for the production of recombinant antibodies
-
Pollock D, Kutzko JP, Birck-Wilson E, et al. Transgenic milk as a method for the production of recombinant antibodies. J Immunol Methods 1999; 231: 147-57
-
(1999)
J Immunol Methods
, vol.231
, pp. 147-157
-
-
Pollock, D.1
Kutzko, J.P.2
Birck-Wilson, E.3
-
77
-
-
0037343212
-
Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures
-
Konkle BA, Bauer KA, Weinstein R, et al. Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. Transfusion 2003; 43: 390-4
-
(2003)
Transfusion
, vol.43
, pp. 390-394
-
-
Konkle, B.A.1
Bauer, K.A.2
Weinstein, R.3
-
78
-
-
0032712090
-
Dolly, Polly and other 'ollys': Likely impact of cloning technology on biomédical uses of livestock
-
Colman A. Dolly, Polly and other 'ollys': likely impact of cloning technology on biomédical uses of livestock. Genet Anal 1999; 15: 167-73
-
(1999)
Genet Anal
, vol.15
, pp. 167-173
-
-
Colman, A.1
-
79
-
-
0034003241
-
Technology evaluation: Transgenic alpha-1-antitrypsin (AAT), PPL therapeutics
-
Tebbutt SJ. Technology evaluation: transgenic alpha-1-antitrypsin (AAT), PPL therapeutics. Curr Opin Mol Ther 2000; 2: 199-204
-
(2000)
Curr Opin Mol Ther
, vol.2
, pp. 199-204
-
-
Tebbutt, S.J.1
-
80
-
-
10744227635
-
Production of cloned pigs by whole-cell intracytoplasmic microinjection
-
Lee JW, Wu SC, Tian XC, et al. Production of cloned pigs by whole-cell intracytoplasmic microinjection. Biol Reprod 2003; 69: 995-1001
-
(2003)
Biol Reprod
, vol.69
, pp. 995-1001
-
-
Lee, J.W.1
Wu, S.C.2
Tian, X.C.3
-
82
-
-
0034050904
-
Evidence for gene transfer and expression of factor IX in haemophilia B treated with an AAV vector
-
Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B treated with an AAV vector. Nat Genet 2000; 24: 257-61
-
(2000)
Nat Genet
, vol.24
, pp. 257-261
-
-
Kay, M.A.1
Manno, C.S.2
Ragni, M.V.3
-
83
-
-
0041532434
-
Adeno-associated virus-mediated gene transfer for hemophilia B
-
High KA. Adeno-associated virus-mediated gene transfer for hemophilia B. Int J Hematol 2002; 76: 310-8
-
(2002)
Int J Hematol
, vol.76
, pp. 310-318
-
-
High, K.A.1
-
84
-
-
0035822005
-
Non viral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A
-
Roth DA, Tawa NE, O'Brien J, et al. Non viral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med 2001; 344: 1735-42
-
(2001)
N Engl J Med
, vol.344
, pp. 1735-1742
-
-
Roth, D.A.1
Tawa, N.E.2
O'Brien, J.3
|